Innate Pharma SA (IPHYF) Stock Statistics & Valuation Metrics

Innate Pharma SA has a market cap or net worth of $185.59M. The enterprise value is $99.32M.

Innate Pharma SA has 92,183,525 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma SA’s return on equity (ROE) is -5.60 and return on invested capital (ROIC) is -51.45%.

The current PE Ratio of Innate Pharma SA is ―. Innate Pharma SA’s PEG ratio is -0.00434.

In the last 12 months, Innate Pharma SA had revenue of 12.62M and earned -49.47M in profits. Earnings per share was -0.61.

In the last 12 months, operating cash flow was -41.10M and capital expenditures -166.00K, giving a free cash flow of -41.26M billion.

Innate Pharma SA pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma SA upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).

Innate Pharma SA as a current ratio of 2.60, with Debt / Equity ratio of 525.45%

In the past 12 months, Innate Pharma SA has paid -7.49M in taxes.

Innate Pharma SA EV to EBITDA ratio is -1.61, with an EV/FCF ratio of -11.28.

Innate Pharma SA has $60.03M in cash and marketable securities with $27.03M in debt, giving a net cash position of $33.00M billion.

Gross margin is -243.65%, with operating margin of -408.61%, and net profit margin of -391.94%.

The average price target for Innate Pharma SA is $2.60, which is 11.43% higher than the current price. The consensus rating is Hold